Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: A French retrospective multicenter cohort study

Transfusion

Volumn 55, Issue 10, 2015, Pages 2445-2451

  Toussaint Hacquard, Marie ^a   Coppo, Paul ^b,c,d   Soudant, Marc ^e   Chevreux, Lysiane ^a   Mathieu Nafissi, Suzanne ^a   Lecompte, Thomas ^a,f   Gross, Sylvie ^a   Guillemin, Francis ^e   Schneider, Thierry ^g  

^a EFS Lorraine Champagne   (France)

^b Centre National de Référence des Microangiopathies Thrombotiques   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e UNIVERSITÉ DE LORRAINE   (France)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FOLIC ACID; FRESH FROZEN PLASMA; QUARANTAINE FRESH FROZEN PLASMA; SOLVENT; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; ENZYME DEFICIENCY; FEMALE; FRENCHMAN; HUMAN; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; IDIOPATHIC DISEASE; IDIOPATHIC THROMBOTIC THROMBOCYTOPENIC PURPURA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PLASMA; PLASMA VOLUME; PLASMAPHERESIS; PROSPECTIVE STUDY; REMISSION; RETROSPECTIVE STUDY; SURVIVAL; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FRANCE; MIDDLE AGED; MORTALITY; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REGISTER; SURVIVAL RATE;

ADULT; DISEASE-FREE SURVIVAL; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; PLASMA; PLASMA EXCHANGE; PLATELET COUNT; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84943739625     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13229     Document Type: Article

References (27)

1. Rock G, Shumak, K, Buskard N, et al., Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-7.
2. Pelletier JP, Transue S, Snyder EL., Pathogen inactivation techniques. Best practice and research. Best Pract Res Clin Haematol 2006; 19: 205-42.
3. Hacquard M, Lecompte T, Belcour B, et al., Evaluation of the hemostatic potential including thrombin generation of three different therapeutic pathogen-reduced plasmas. Vox Sang 2012; 102: 354-61.
4. Sacher R, Pehta J, Zarou C, et al., Solvent detergent-treated plasma versus fresh frozen plasma in patients with thrombotic thrombocytopenic purpura [abstract]. Transfusion 1996; 36 Suppl 95: S252.
5. Horowitz MS, Pehta JC., SD plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang 1998; 74 Suppl 1: 231-5.
6. Mintz PD, Neff A, MacKenzie M, et al., A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006; 46: 1693-704.
7. de la Rubia J, Arriaga F, Linares D, et al., Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2001; 114: 721-3.
8. Alvarez-Larrán A, Del Río J, Ramírez C, et al., Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004; 86: 246-51.
9. del Río-Garma J, Alvarez-Larrán A, Martínez C, et al., Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. Br J Haematol 2008; 143: 39-45.
10. Brunskill SJ, Tusold A, Benjamin S, et al., A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Transfus Med 2007; 17: 17-35.
11. Michael M, Elliott EJ, Craig JC, et al., Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009; 53: 259-72.
12. Yang L, Stanworth S, Hopewell S, et al., Is fresh-frozen plasma clinically effective? An update of a systematic review of randomized controlled trials. Transfusion 2012; 52: 1673-86.
13. Coppo P, Schwarzinger M, Buffet M, et al., Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One 2010; 5: e10208.
14. Ferrari S, Scheiflinger F, Rieger M, et al., Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007; 109: 2815-22.
15. Coppo P, Veyradier A., Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura. Presse Med 2012; 41: e163-76.
16. Froissart A, Buffet M, Veyradier A, et al., Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 2012; 40: 104-11.
17. Agence Nationale de Sécurité du médicament et des produits de santé (ANSM)/Haute Autorité de Santé (HAS). Recommandations. Transfusion de plasma thérapeutique: produits, indications, argumentaire. Haute Autorité de Santé (HAS); 2012 [cited 2015 Feb 23]. Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-06/12irp07-argu-transfusion-de-plasma.pdf
18. Marubini E, Valsecchi MG., Analyzing survival data from clinical trials and observational studies. New York: Wiley; 1995.
19. Gray R., A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-54.
20. Fine PF, Gray RJ., A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
21. Hovinga JA, Vesely SK, Terrell DR, et al., Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-11.
22. Howard M, Williams L, Terrell D, et al., Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2006; 46: 154-6.
23. Benhamou Y, Assié C, Boelle PY, et al., Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica 2012; 97: 1181-6.
24. McLeod B., Plasma and plasma derivatives in therapeutic plasmapheresis [abstract]. Transfusion 2012; 52: 38S-44S.
25. Schneider T, Hacquard M, Lecompte T., Indications for different types of plasma in hematological diseases. Hématologie 2009; 15: 1-8.
26. Bost V, Odent-Malaure H, Chavarin P, et al., A regional haemovigilance retrospective study of four types of therapeutic plasma in a ten-year survey period in France. Vox Sang 2013; 104: 337-41.
27. Benjamin RJ, McLaughlin LS., Plasma components: properties, differences, and uses [abstract]. Transfusion 2012; 52: 9S-19S.